Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085488 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00085488: Completed Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT00085488 is a Phase 1 study that has completed, run by Dartmouth-Hitchcock Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085488, a Phase 1 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.
Interventions
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL therapeutic autologous dendritic cells
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-02 |
| Est. Completion | 2006-02 |
| Phase | Phase 1 |
What the finished NCT00085488 record still lists
NCT00085488 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which autologous tumor cell vaccine is the first listed.
NCT00085488 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00085488 about?
NCT00085488 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.
What is the current status of trial NCT00085488?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-02. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00085488?
The interventions under investigation include: autologous tumor cell vaccine (BIOLOGICAL), therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00085488?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia